Literature DB >> 34977967

Differences in the incidence of aflibercept-related sterile endophthalmitis according to types of disposable syringes used.

Minjeong Kim1, Jee Taek Kim2.   

Abstract

PURPOSE: To evaluate the difference between the incidences of sterile endophthalmitis after administration of intravitreal aflibercept injection using two different types of syringes.
METHODS: We administered a total of 498 intravitreal aflibercept injections between September 2017 and August 2021. The disposable syringe used was changed from a 1-mL disposable syringe (Profi syringe, Shinchang Medical., Ltd. Korea) to a 1-mL Becton Dickenson Luer-Lok syringe (BD, Franklin, NJ, USA) in September 2019. Thus, the patients who received injections before and after September 1, 2019, were classified into group 1 and group 2, respectively. The incidence of aflibercept-related sterile endophthalmitis between the two groups was compared.
RESULTS: In group 1, six (2.791%) out of 215 cases were diagnosed with sterile endophthalmitis and prescribed topical or oral steroids. In group 2, one (0.353%) out of 283 cases was diagnosed with sterile endophthalmitis and prescribed a steroid eye drop. The incidence of sterile endophthalmitis was significantly different between the two groups (P = 0.046).
CONCLUSION: The BD Luer-Lok syringe is associated with a lower incidence of aflibercept-related sterile endophthalmitis than the conventional polypropylene syringe. Differences in immunogenicity associated with silicone oil lubricants within the syringes might be one of the potential reasons behind the difference in the incidence of the sterile endophthalmitis.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Aflibercept; Intravitreal injection; Silicone oil; Sterile endophthalmitis

Mesh:

Substances:

Year:  2022        PMID: 34977967     DOI: 10.1007/s00417-021-05454-z

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  24 in total

1.  A study of the interaction of selected drugs and plastic syringes.

Authors:  T J Speaker; S J Turco; D A Nardone; J E Miripol
Journal:  J Parenter Sci Technol       Date:  1991 Sep-Oct

2.  Inflammatory Reaction After Aflibercept Intravitreal Injections Associated With Silicone Oil Droplets Released From Syringes: A Case-Control Study.

Authors:  Gustavo Barreto Melo; Ana Carolina Migliorini Figueira; Fernanda Aparecida Heleno Batista; Acácio Alves Souza Lima Filho; Eduardo Büchele Rodrigues; Rubens Belfort; Maurício Maia
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2019-05-01       Impact factor: 1.300

3.  Ranibizumab for neovascular age-related macular degeneration.

Authors:  Philip J Rosenfeld; David M Brown; Jeffrey S Heier; David S Boyer; Peter K Kaiser; Carol Y Chung; Robert Y Kim
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

Review 4.  Immunogenicity of engineered antibodies.

Authors:  William Ying Khee Hwang; Jefferson Foote
Journal:  Methods       Date:  2005-05       Impact factor: 3.608

5.  Noninfectious inflammation after intravitreal injection of aflibercept: clinical characteristics and visual outcomes.

Authors:  Roger A Goldberg; Chirag P Shah; Torsten W Wiegand; Jeffrey S Heier
Journal:  Am J Ophthalmol       Date:  2014-06-28       Impact factor: 5.258

6.  Postmarketing analysis of aflibercept-related sterile intraocular inflammation.

Authors:  Paul Hahn; Mina M Chung; Harry W Flynn; Suber S Huang; Judy E Kim; Tamer H Mahmoud; SriniVas R Sadda; Pravin U Dugel
Journal:  JAMA Ophthalmol       Date:  2015-04       Impact factor: 7.389

7.  NONINFECTIOUS VITRITIS AFTER INTRAVITREAL INJECTION OF ANTI-VEGF AGENTS: Variations in Rates and Presentation by Medication.

Authors:  Patrick D Williams; Deborah Chong; Timothy Fuller; David Callanan
Journal:  Retina       Date:  2016-05       Impact factor: 4.256

Review 8.  Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop.

Authors:  Douglas A Jabs; Robert B Nussenblatt; James T Rosenbaum
Journal:  Am J Ophthalmol       Date:  2005-09       Impact factor: 5.258

9.  Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab.

Authors:  Nicholas Papadopoulos; Joel Martin; Qin Ruan; Ashique Rafique; Michael P Rosconi; Ergang Shi; Erica A Pyles; George D Yancopoulos; Neil Stahl; Stanley J Wiegand
Journal:  Angiogenesis       Date:  2012-06       Impact factor: 9.596

Review 10.  Anti-VEGF Therapy and the Retina: An Update.

Authors:  Vikas Tah; Harry O Orlans; Jonathan Hyer; Edward Casswell; Nizar Din; Vishnu Sri Shanmuganathan; Louise Ramskold; Saruban Pasu
Journal:  J Ophthalmol       Date:  2015-08-31       Impact factor: 1.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.